Journal article
Association of Brain Age, Lesion Volume, and Functional Outcome in Patients With Stroke
SL Liew, N Schweighofer, JH Cole, A Zavaliangos-Petropulu, BP Lo, LKM Han, T Hahn, L Schmaal, MR Donnelly, JN Jeong, Z Wang, A Abdullah, JH Kim, A Hutton, G Barisano, MR Borich, LA Boyd, A Brodtmann, CM Buetefisch, WD Byblow Show all
Neurology | Published : 2023
Abstract
Background and Objectives Functional outcomes after stroke are strongly related to focal injury measures. However, the role of global brain health is less clear. In this study, we examined the impact of brain age, a measure of neurobiological aging derived from whole-brain structural neuroimaging, on poststroke outcomes, with a focus on sensorimotor performance. We hypothesized that more lesion damage would result in older brain age, which would in turn be associated with poorer outcomes. Related, we expected that brain age would mediate the relationship between lesion damage and outcomes. Finally, we hypothesized that structural brain resilience, which we define in the context of stroke as ..
View full abstractGrants
Awarded by National Science Foundation
Funding Acknowledgements
A.G. Brodtmann is supported by Australian National Health and Medical Research Council (NHMRC) GNT1020526,GNT1045617(AB), GNT1094974; Brain Foundation; Wicking Trust; Collie Trust; Sidney and Fiona Myer Family Foundation; and Heart Foundation Future Leader Fellowship 100784. C.M. Buetefisch is supported by NIH R01NS090677. W.D. Byblow is supported by the Health Research Council of New Zealand. J.M. Cassidy is supported by NIH R00 HD091375. A.B. Conforto is supported by NIH R01 NS076348; IIEP-2250-14. S.C. Cramer is supported by U01 NS120910, R01 HD095457, and R01NR015591. A.N. Dula is supported by Lone Star Stroke Research Consortium. N. Egorova-Brumley is supported by Melbourne Research Fellowship. F. Geranmayeh is supported by Wellcome Trust (093957). L.K.M. Han is supported by a Rubicon fellowship provided by The Dutch Research Council (NWO). T. Hahn is supported by the German Research Foundation (DFG grants HA7070/2-2, HA7070/3, HA7070/4 to T.H.). B. Hordacre is supported by National Health and Medical Research Council (NHMRC) fellowship (GNT1125054). S.A. Kautz is supported by NIH P20 GM109040, 1IK6RX003075. M.S. Khlif is supportedby National Health and Medical Research Council (NHMRC) grant (APP1020526). S.-L. Liew is supported by NIH R01NS115845. B.J. MacIntosh is supported by Canadian Partnership for Stroke Recovery, Sandra E Black Centre for Brain Resilience & Recovery. M. Mataro is supported by ICREA Academia program.F. Piras is supported by Italian Ministry of Health, Ricerca Corrente, RC 21, 22. K.P. Revill is supported by NIH R01NS090677.H.M. Schambra is supported by National Institute of Neurological Disorders and Stroke (NINDS) R01 NS110696. L. Schmaal is supported by National Institute of Mental Health of the NIH(R01MH117601) and by a National Health and Medical Research Council (NHMRC) Career Development Fellowship (1140764).N. Schweighofer is supported by NIH R56 NS100528. N.J. Seo is supported by NIH/NICHD 1R01HD094731-01A1, VA RR&DI01 RX003066, U54-GM104941, and P20GM109040. S.R. Soekadar is supported by the European Research Council (ERC)grant 759370. G. Spalletta is supported by Italian Ministry of Health, RC 18-19-20-21-22/A. C.M. Stinear is supported by Health Research Council of New Zealand. M. Taga is supported by NIH R01 NS110696. G. Thielman is supported by Temple University subaward of NIH R24-NHLBI (Dr. Mickey Selzer) Center for Experimental Neurorehabilitation Training. P.M. Thompson is supported by NIH U54 EB020403. L.T. Westlye is supported by European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG, grant 802998), the Research Council of Norway (298646, 300767), and the South-Eastern Norway Regional Health Authority (2019101). C.J. Winstein is supported by grants HD065438 and NS100528. G.F. Wittenberg is supported by VA RR&D program, NSF, and serveson the Medical Advisory Board of Myomo, Inc., a manufacturer of rehabilitation-related equipment. S.L. Wolf is supported by VASPiRE 1I21RX003581-01 grant 13039842; REGE19000049 NIH-NIDILRR RERC Program; NIH NICHD 1R01HD095975-01A1; NINDS U01 NS102353; NINDS U01 NINDS NS166655;and NINDS1U10NS086607.